β2-adrenoceptor stimulation inhibits advanced glycation end products-induced adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells

Hideo Kohka Takahashi, Shuji Mori, Keyue Liu, Hidenori Wake, Jiyong Zhang, Rui Liu, Tadashi Yoshino, Masahiro Nishibori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cell-to-cell interaction through binding of intercellular adhesion molecule-1 (ICAM-1) and CD40 on monocytes to their ligands on T-cells plays crucial roles in cytokine production. Advanced glycation end products (AGEs) subtypes induce complications in diabetes. In a previous study, we found that glyceraldehyde-derived AGE (AGE-2) and glycolaldehyde-derived AGE (AGE-3) at 100 μg/ml induced the expressions of ICAM-1 and CD40 on monocytes and the production of interferon (IFN)-γ and tumor necrosis factor (TNF)-α in human peripheral blood mononuclear cells. β2-adrenoceptor stimulation has been demonstrated to modulate the production of inflammatory mediators. In the present study, we found that norepinephrine, epinephrine and isoproterenol inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production in a concentration-dependent manner. The action of these catecholamines was antagonized by β2-adrenoceptor antagonist, but not by α1-, α2- and β1-adrenoceptor antagonist. β2-adrenoceptor agonists, salbutanol and terbutaline inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production, but α1-, α2- and β1-adrenoceptor agonist had no effect, indicating that the stimulation of β2-adrenoceptor might improve AGEs-initiated complications in diabetes.

Original languageEnglish
Pages (from-to)313-317
Number of pages5
JournalEuropean Journal of Pharmacology
Volume627
Issue number1-3
DOIs
Publication statusPublished - Feb 10 2010

Fingerprint

Advanced Glycosylation End Products
Adrenergic Receptors
Blood Cells
Cytokines
Intercellular Adhesion Molecule-1
Diabetes Complications
Monocytes
Glyceraldehyde
Terbutaline
Isoproterenol
Cell Communication
Interferons
Epinephrine
Catecholamines
Norepinephrine
Ligands
T-Lymphocytes

Keywords

  • β-adrenoceptor
  • Adhesion molecule
  • Advanced glycation end product
  • Monocyte

ASJC Scopus subject areas

  • Pharmacology

Cite this

β2-adrenoceptor stimulation inhibits advanced glycation end products-induced adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. / Takahashi, Hideo Kohka; Mori, Shuji; Liu, Keyue; Wake, Hidenori; Zhang, Jiyong; Liu, Rui; Yoshino, Tadashi; Nishibori, Masahiro.

In: European Journal of Pharmacology, Vol. 627, No. 1-3, 10.02.2010, p. 313-317.

Research output: Contribution to journalArticle

@article{b26b10d493b442239b0f45d59f61b53c,
title = "β2-adrenoceptor stimulation inhibits advanced glycation end products-induced adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells",
abstract = "Cell-to-cell interaction through binding of intercellular adhesion molecule-1 (ICAM-1) and CD40 on monocytes to their ligands on T-cells plays crucial roles in cytokine production. Advanced glycation end products (AGEs) subtypes induce complications in diabetes. In a previous study, we found that glyceraldehyde-derived AGE (AGE-2) and glycolaldehyde-derived AGE (AGE-3) at 100 μg/ml induced the expressions of ICAM-1 and CD40 on monocytes and the production of interferon (IFN)-γ and tumor necrosis factor (TNF)-α in human peripheral blood mononuclear cells. β2-adrenoceptor stimulation has been demonstrated to modulate the production of inflammatory mediators. In the present study, we found that norepinephrine, epinephrine and isoproterenol inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production in a concentration-dependent manner. The action of these catecholamines was antagonized by β2-adrenoceptor antagonist, but not by α1-, α2- and β1-adrenoceptor antagonist. β2-adrenoceptor agonists, salbutanol and terbutaline inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production, but α1-, α2- and β1-adrenoceptor agonist had no effect, indicating that the stimulation of β2-adrenoceptor might improve AGEs-initiated complications in diabetes.",
keywords = "β-adrenoceptor, Adhesion molecule, Advanced glycation end product, Monocyte",
author = "Takahashi, {Hideo Kohka} and Shuji Mori and Keyue Liu and Hidenori Wake and Jiyong Zhang and Rui Liu and Tadashi Yoshino and Masahiro Nishibori",
year = "2010",
month = "2",
day = "10",
doi = "10.1016/j.ejphar.2009.10.034",
language = "English",
volume = "627",
pages = "313--317",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - β2-adrenoceptor stimulation inhibits advanced glycation end products-induced adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells

AU - Takahashi, Hideo Kohka

AU - Mori, Shuji

AU - Liu, Keyue

AU - Wake, Hidenori

AU - Zhang, Jiyong

AU - Liu, Rui

AU - Yoshino, Tadashi

AU - Nishibori, Masahiro

PY - 2010/2/10

Y1 - 2010/2/10

N2 - Cell-to-cell interaction through binding of intercellular adhesion molecule-1 (ICAM-1) and CD40 on monocytes to their ligands on T-cells plays crucial roles in cytokine production. Advanced glycation end products (AGEs) subtypes induce complications in diabetes. In a previous study, we found that glyceraldehyde-derived AGE (AGE-2) and glycolaldehyde-derived AGE (AGE-3) at 100 μg/ml induced the expressions of ICAM-1 and CD40 on monocytes and the production of interferon (IFN)-γ and tumor necrosis factor (TNF)-α in human peripheral blood mononuclear cells. β2-adrenoceptor stimulation has been demonstrated to modulate the production of inflammatory mediators. In the present study, we found that norepinephrine, epinephrine and isoproterenol inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production in a concentration-dependent manner. The action of these catecholamines was antagonized by β2-adrenoceptor antagonist, but not by α1-, α2- and β1-adrenoceptor antagonist. β2-adrenoceptor agonists, salbutanol and terbutaline inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production, but α1-, α2- and β1-adrenoceptor agonist had no effect, indicating that the stimulation of β2-adrenoceptor might improve AGEs-initiated complications in diabetes.

AB - Cell-to-cell interaction through binding of intercellular adhesion molecule-1 (ICAM-1) and CD40 on monocytes to their ligands on T-cells plays crucial roles in cytokine production. Advanced glycation end products (AGEs) subtypes induce complications in diabetes. In a previous study, we found that glyceraldehyde-derived AGE (AGE-2) and glycolaldehyde-derived AGE (AGE-3) at 100 μg/ml induced the expressions of ICAM-1 and CD40 on monocytes and the production of interferon (IFN)-γ and tumor necrosis factor (TNF)-α in human peripheral blood mononuclear cells. β2-adrenoceptor stimulation has been demonstrated to modulate the production of inflammatory mediators. In the present study, we found that norepinephrine, epinephrine and isoproterenol inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production in a concentration-dependent manner. The action of these catecholamines was antagonized by β2-adrenoceptor antagonist, but not by α1-, α2- and β1-adrenoceptor antagonist. β2-adrenoceptor agonists, salbutanol and terbutaline inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production, but α1-, α2- and β1-adrenoceptor agonist had no effect, indicating that the stimulation of β2-adrenoceptor might improve AGEs-initiated complications in diabetes.

KW - β-adrenoceptor

KW - Adhesion molecule

KW - Advanced glycation end product

KW - Monocyte

UR - http://www.scopus.com/inward/record.url?scp=73449135750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449135750&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2009.10.034

DO - 10.1016/j.ejphar.2009.10.034

M3 - Article

C2 - 19857486

AN - SCOPUS:73449135750

VL - 627

SP - 313

EP - 317

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -